Janssen Pharma, Russia's NewVac To Develop Cancer-Treatment Drug
This article was originally published in PharmAsia News
Executive Summary
Janssen Pharmaceuticals and NewVac have signed an agreement to share development and marketing rights for the U.S. drug maker's quisinostat for treating solid tumors along with standard care in Eastern Europe.
Janssen Pharmaceuticals and NewVac have signed an agreement to share development and marketing rights for the U.S. drug maker's quisinostat for treating solid tumors along with standard care in Eastern Europe. The pact calls for NewVac, a unit of ChemRar High Tech Center for life sciences, to provide Janssen with research-and-development support through the trials. In return, Janssen is to offer its expertise in conducting clinical trials outside of Russia, with a focus on several other Eastern Europe markets. (Click here for more
)
"Janssen's Cancer Drug Goes To Russia" - Chemrar (Russia) (1/11/2013)